Safety and Immunogenicity of a Yeast-Derived Recombinant Hepatitis B Vaccine in Bulgarian Newborns

[1]  W. Magdzik.  Hepatitis B epidemiology in Poland, Central and Eastern Europe and the newly independent states. , 2000, Vaccine.

[2]  H. Whittle,et al.  What level of hepatitis B antibody is protective? , 1999, The Journal of infectious diseases.

[3]  P. Bonanni.  Universal hepatitis B immunization: infant, and infant plus adolescent immunization. , 1998, Vaccine.

[4]  P. van Damme,et al.  Prevention and control of hepatitis B in central and eastern Europe and the newly independent states, Siofok, Hungary, 6-9 October 1996. , 1997, Vaccine.

[5]  H. Margolis,et al.  Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. , 1996, The Pediatric infectious disease journal.

[6]  J. Banatvala,et al.  Hepatitis B vaccine boosting among young healthy adults , 1994, The Lancet.

[7]  G. Filice,et al.  Hepatitis B immunization in infants of hepatitis B surface antigen-negative mothers. , 1993, Pediatrics.

[8]  C. Roure.  Overview of epidemiology and disease burden of hepatitis B in the European region. , 1995, Vaccine.

[9]  Nina Gatcheva,et al.  Implementing universal vaccination programmes: Bulgaria. , 1995, Vaccine.

[10]  S. Medendorp,et al.  Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonates. , 1994, The Pediatric infectious disease journal.

[11]  C. Kunz,et al.  Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects. , 1987, Postgraduate medical journal.